Bio-Path (NASDAQ:BPTH – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
Bio-Path Trading Down 1.0 %
BPTH stock opened at $0.18 on Tuesday. Bio-Path has a twelve month low of $0.12 and a twelve month high of $7.67. The firm’s fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $0.89.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Bio-Path in a research report on Sunday. They set a “sell” rating on the stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading
- Five stocks we like better than Bio-Path
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- ETF Screener: Uses and Step-by-Step Guide
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Investing in Construction Stocks
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
